IMMP vs. PYXS, TSVT, DSGN, HOWL, ALDX, CTNM, ME, FHTX, VERU, and NKTR
Should you be buying Immutep stock or one of its competitors? The main competitors of Immutep include Pyxis Oncology (PYXS), 2seventy bio (TSVT), Design Therapeutics (DSGN), Werewolf Therapeutics (HOWL), Aldeyra Therapeutics (ALDX), Contineum Therapeutics (CTNM), 23andMe (ME), Foghorn Therapeutics (FHTX), Veru (VERU), and Nektar Therapeutics (NKTR). These companies are all part of the "pharmaceutical preparations" industry.
Pyxis Oncology (NASDAQ:PYXS) and Immutep (NASDAQ:IMMP) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, community ranking, analyst recommendations and earnings.
Immutep has higher revenue and earnings than Pyxis Oncology.
39.1% of Pyxis Oncology shares are held by institutional investors. Comparatively, 2.3% of Immutep shares are held by institutional investors. 8.4% of Pyxis Oncology shares are held by company insiders. Comparatively, 3.1% of Immutep shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Pyxis Oncology had 3 more articles in the media than Immutep. MarketBeat recorded 6 mentions for Pyxis Oncology and 3 mentions for Immutep. Pyxis Oncology's average media sentiment score of 0.65 beat Immutep's score of 0.55 indicating that Immutep is being referred to more favorably in the news media.
Pyxis Oncology presently has a consensus target price of $8.80, suggesting a potential upside of 109.52%. Immutep has a consensus target price of $8.50, suggesting a potential upside of 190.10%. Given Pyxis Oncology's higher probable upside, analysts plainly believe Immutep is more favorable than Pyxis Oncology.
Pyxis Oncology has a beta of 1.45, indicating that its share price is 45% more volatile than the S&P 500. Comparatively, Immutep has a beta of 2.1, indicating that its share price is 110% more volatile than the S&P 500.
Immutep received 290 more outperform votes than Pyxis Oncology when rated by MarketBeat users. However, 79.17% of users gave Pyxis Oncology an outperform vote while only 72.37% of users gave Immutep an outperform vote.
Pyxis Oncology's return on equity of 0.00% beat Immutep's return on equity.
Summary
Immutep beats Pyxis Oncology on 8 of the 13 factors compared between the two stocks.
Get Immutep News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
